Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial
Cancer · 01.10.2026 · 132 (19)
DOI: 10.1002/cncr.70549 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 21.09.2026. Verfasst von Stine Ulrik Mikkelsen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Ascorbic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danish Cancer Society, Kræftens Bekæmpelse, Van Andel Institute.
Abstract (Originalsprache)
Background
Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients with clonal cytopenia of undetermined significance (CCUS) or lower risk myeloid malignancies.
Methods
EVITA (Epigenetics, Vitamin C, and Abnormal Hematopoiesis) was a double‐blind, randomized, placebo‐controlled, phase 2 trial conducted in Denmark and the United States. Adults with CCUS or lower risk myeloid malignancies not receiving anticancer therapy were randomly assigned (1:1) to receive oral VitC (1000 mg/day) or placebo for 12 months, followed by long‐term follow‐up. The primary end point was the median clonal growth rate from baseline to end of treatment. EVITA was registered at ClinicalTrials.gov (NCT03682029), and is now completed.
Results
Between November 1, 2017, and September 28, 2022, 109 patients were enrolled (VitC, n = 55; placebo, n = 54). Although the primary end point, median clonal growth rate, did not differ between groups (−0.016; 95% CI, −0.096 to 0.064; p = .70), secondary outcomes included differences in inflammatory cytokine trajectories and fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]). In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025).
Conclusions
These findings suggest oral VitC as a safe, biologically active intervention in patients with early‐stage myeloid malignancies and precursor conditions. A phase 3 trial is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Bioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, Michigan, USA.
- Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan, USA.
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Mathematical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Stine Ulrik Mikkelsen, Ryan Burgos
Förderung
- Danish Cancer Society
- Kræftens Bekæmpelse
- Van Andel Institute
Zitieren
APA
Mikkelsen, S. U., Al-Mousawi, A., Puglisi, A. B., Vallentin, A. P., Mortensen, A. Ø., Madaj, Z., Hinoue, T., Ottesen, H. N., Jespersen, J. S., Gillberg, L., Tulstrup, M., Hansen, N. R., Hansen, J. W., Andersen, M. K., Thomas, S. L., Isaguirre, C., Sheldon, R., Adams, M., Burgos, R., …, & Grønbæk, K. (2026). Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial. Cancer, 132(19). https://doi.org/10.1002/cncr.70549
Vancouver
Mikkelsen SU, Al-Mousawi A, Puglisi AB, Vallentin AP, Mortensen AØ, Madaj Z, et al. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial. Cancer. 2026;132(19). doi:10.1002/cncr.70549
BibTeX
@article{Mikkelsen2026,
author = {Mikkelsen, Stine Ulrik and Al-Mousawi, Ali and Puglisi, Amalie Bach and Vallentin, Anders Pommer and Mortensen, Astrid Østergaard and Madaj, Zachary and Hinoue, Toshinori and Ottesen, Heidi Naomi and Jespersen, Jakob Schmidt and Gillberg, Linn and Tulstrup, Morten and Hansen, Niels Richard and Hansen, Jakob Werner and Andersen, Mette Klarskov and Thomas, Stacey Lyn and Isaguirre, Christine and Sheldon, Ryan and Adams, Marie and Burgos, Ryan and Baylin, Stephen and Mortensen, Bo Kok and Lee O'Connell, Casey and Tang Severinsen, Marianne and Laird, Peter William and Lykkesfeldt, Jens and Jones, Peter and Grønbæk, Kirsten},
title = {Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial},
journal = {Cancer},
year = {2026},
volume = {132},
number = {19},
doi = {10.1002/cncr.70549}
}
EUVIMED